New data from ASH 2017 raise many questions regarding how these new approaches will fit into the current treatment paradigm for patients with myeloma.
Carol Ann Huff, MD, discusses the clinical impact of the monoclonal antibody daratumumab for the treatment of patients with multiple myeloma, with practical insights for using this agent in your practice.
Shaji Kumar, MD, provides an overview of the latest research on smoldering multiple myeloma, with treatment strategies to consider for your patients.
Expert commentary on the clinical implications of the OPTIMISMM trial of pomalidomide combinations in early-relapse multiple myeloma.
Now that 3 effective proteasome inhibitors are approved by the FDA for multiple myeloma, read how to select the optimal agent for your patients considering dosing, safety profiles, and efficacy in risk-defined subgroups.
New data for managing lenalidomide-refractory patients, evolving carfilzomib dosing, and CAR T-cell therapy hold significant potential to improve outcomes in relapsed/refractory multiple myeloma.
Examine best practice treatment options for patients with transplantation-eligible and transplantation-ineligible multiple myeloma, with expert commentary and interactive cases.
In this downloadable slideset from the multiple myeloma online program, Shaji Kumar, MD, provides expert perspective for the optimal management of patients with multiple myeloma.
In this video, Sagar Lonial, MD, provides insight on diagnosis and optimal management of patients with smoldering myeloma, based on current clinical evidence.
Watch this video to hear when Sagar Lonial, MD, recommends transplantation for his patients with newly diagnosed myeloma.
Watch this video to see how Sagar Lonial, MD, uses genetic and disease risk factors to personalize maintenance strategies after autologous SCT for his patients with multiple myeloma.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.